Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSAT | LXEO |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 348.7M |
| IPO Year | 2021 | 2023 |
| Metric | TSAT | LXEO |
|---|---|---|
| Price | $47.44 | $3.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $37.00 | $18.44 |
| AVG Volume (30 Days) | 102.0K | ★ 896.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.01 | $3.27 |
| 52 Week High | $61.54 | $10.99 |
| Indicator | TSAT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 19.53 |
| Support Level | $41.65 | N/A |
| Resistance Level | $52.11 | $5.38 |
| Average True Range (ATR) | 2.76 | 0.24 |
| MACD | -0.14 | -0.12 |
| Stochastic Oscillator | 22.59 | 0.61 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.